In The Spotlight

Shares of Virpax Pharmaceuticals Inc. (VRPX) are down more than 80% from their high of $36, recorded in August of this year, and trade around $4.

Shares of Freeline Therapeutics Holdings plc (FRLN) have lost nearly 83% year-to-date and trade around $3. The company's lead product candidate is FLT180a, a next-generation AAV gene therapy for the treatment of Haemophilia B.

Shares of Harmony Biosciences Holdings Inc. (HRMY) have gained 42% over the last three months to trade around $39. The company markets Wakix for the treatment of excessive daytime sleepiness in adults with narcolepsy. It is the first and only FDA approved non-scheduled treatment option for narcolepsy. The clinical utility of Wakix is also being explored beyond narcolepsy.

Shares of 4D Molecular Therapeutics Inc. (FDMT) have more than halved from their 52-week high of $54.98, recorded in March of this year, to trade around $26.

Shares of Xenon Pharmaceuticals Inc. (XENE) closed Monday's trading at an all-time high of $31.50, gaining more than 100%, thanks to promising mid-stage data for focal epilepsy drug XEN1101.

After an upbeat fiscal first quarter, AngioDynamics Inc. (ANGO) appears confident in its future as it continues to execute its strategic plan of transformation into a high-growth Med Tech company.

Shares of Prothena Corp. plc (PRTA), which closed at an all-time high of $77.39 on Monday, are up 544% year-to-date, thanks to the company's strategic partnerships and progress across its portfolio. We had alerted our premium subscribers to PRTA on Aug.28, 2019, when it was trading around $8.78, in our report titled "Striving to regain lost glory...".

The company we are profiling today is KalVista Pharmaceuticals Inc. (KALV), which is developing a franchise of oral treatments for HAE - both on-demand and prophylactic HAE drugs.

Shares of Doximity Inc. (DOCS) touched an all-time high of $104.98 in intraday trading Friday (Sep.3, 2021) and that reflects a gain of nearly 155% in just 51 trading days. Given the rapid adoption of virtual and online care tools, Doximity, which now serves over 30% of all US physicians with its paid telehealth offering, is well worth watching.

F-star Therapeutics Inc. (FSTX), a clinical-stage biopharmaceutical company developing next generation bispecific immunotherapies, has a couple of catalysts to watch in the coming months. Will the data readouts add shine to the stock?